.no-js-message{position:fixed;top:0;left:0;right:0;background:#222;color:#fff;padding:8px 12px;font-size:14px;z-index:10000;text-align:center}JavaScript is disabled. The site works, but some features may be limited.

INDIA
MONEY
TRAVELLER
EATS
RESPAWN
LUXE

Get magazine delivered to your doorstep

Get latest issue delivered instantly

Only in Delhi-NCR, Mumbai, Bengaluru, Pune, Lucknow & Kolkata

Delivery within India

Delivery outside India

Get magazine delivered to your doorstep

Get latest issue delivered instantly

Only in Delhi-NCR, Mumbai, Bengaluru, Pune, Lucknow & Kolkata

Markets
News
Corporate
- Corporate Strategist
- Down the Ages
AI
Magazine
OB DataLens
In Depth
Economy & Policy
- Nash Equilibria
Videos
Start-Up
Planet

News
Magazine
Markets
In Depth
Economy & Policy
- Nash Equilibria
Videos
Start-Up
Planet
Corporate
- Corporate Strategist
- Down the Ages
Tech
AI
Budget 2025
Spotlight
Magazine Special Edition
Initiatives
- Spotlight
- C3
About Us

Markets
News
Corporate
AI
Magazine
OB DataLens
In Depth
Economy & Policy
Videos
Start-Up
Planet

home
Topic
Pharmaceutical

Pharmaceutical

Biocon

Biocon Considers $1.5 Billion Sale Of Generic API Business To Cut Debt

BY Outlook Business Desk

Second Covid Wave Pushes Indias Pharma Industry Growth to 59% in April

India's Pharma Biz Can Reach USD 130 Billion By 2030: Industry Experts

BY Press Trust of India

Second Covid Wave Pushes Indias Pharma Industry Growth to 59% in April

AstraZeneca Pharma India Plans To Sell Bengaluru Plant

BY Press Trust of India

Glenmark Gets Tentative Approval From USFDA For Generic Psoriasis Foam

Glenmark Gets Tentative Approval From USFDA For Generic Psoriasis Foam

BY PTI

Pharmaceutical Sector

Alembic Subsidiary Gets USFDA Nod For Plaque Psoriasis Treatment Foam

BY PTI

Pandemic Leads To A Dip In Demand For Talent In Healthcare, BFSI

Pandemic Leads To A Dip In Demand For Talent In Healthcare, BFSI

BY Aparajita Gupta

Sun Pharmaceuticals - A Specialty player

Sun Pharmaceuticals - A Specialty player

Advertisement

Woes for Cipla

Woes for Cipla

Close Ad

Group Publications

About Us
Contact Us
Terms and Conditions
Privacy Policy

Copyright © 2025 Outlook Publishing India Pvt Ltd.

Copyright © 2025 Outlook Publishing India Pvt Ltd. All pages of the Website are subject to our terms and conditions and privacy policy. You must not reproduce, duplicate, copy, sell, resell or exploit any material on the Website for any commercial purposes.